Eloralintide Peptide: Research Guide to Lilly’s LY3841136 (2026)
Reviewed by
Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant
Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.
The eloralintide peptide (LY3841136) is Eli Lilly’s investigational once-weekly amylin receptor agonist, and in its 48-week Phase 2 trial the 9 mg weekly dose produced a body-weight change of −20.1% against −0.4% for placebo in a 263-participant study of adults with obesity or overweight but without type 2 diabetes. That result, published in The Lancet on November 6, 2025, is the reason the molecule reached three Phase 3 trials within months. This hub guide covers the molecule, its pharmacology, its half-life and every human dataset published so far.
The eloralintide peptide is not approved by the FDA or any other regulator anywhere in the world as of October 2026; Lilly’s own information page calls it investigational throughout, and that status applies equally to the single 10 mg lyophilized eloralintide research vial sold by PSPeptides for laboratory use. Everything below comes from Lilly’s publications, press releases and trial registry pages, and nothing here should be read as a treatment claim.
Lilly developed the eloralintide peptide under the internal code LY3841136 and states that it was “designed to preferentially activate the amylin 1 receptor (AMY1R)” and that “in clinical trials, it was self-injected once weekly” (Lilly, What to know about eloralintide). The company is also testing it alongside tirzepatide under the name EloraTZP and plans Phase 3 studies of a co-formulation by the end of 2026.
What Is Eloralintide? The Research Picture at a Glance
| Item | Detail (as of October 2026) | Source |
|---|---|---|
| Developer and code | Eli Lilly; LY3841136 | Lilly information page |
| Drug class | Once-weekly subcutaneous amylin receptor agonist, designed to preferentially activate AMY1R | Lilly information page |
| Regulatory status | Investigational; not approved by any regulator; three Phase 3 trials under way | Lilly information page; Lilly Trials |
| Structure | 37-amino-acid analogue of human amylin; three non-coded residues; methylene thioacetal bridge; C20 fatty diacid on Lys26 | Briere et al. 2025 |
| Terminal half-life | 310–366 hours (12.9–15.3 days) after single doses; about 14 days with weekly dosing | Briere et al. 2025; Bhattachar et al. 2026 |
| Doses studied in humans | 0.04–12 mg single doses; 1.2–12 mg weekly for 12 weeks; 1–9 mg weekly for 48 weeks | Briere; Bhattachar; Billings |
| Phase 2 weight change (48 weeks, without type 2 diabetes) | −9.5% (1 mg) to −20.1% (9 mg) versus −0.4% placebo, efficacy estimand | Lilly press release, Nov 6, 2025 |
| Phase 2 nausea | 11.1% to 64.3% by arm; pooled 32.7%; placebo 13.5% | Billings et al. 2025 |
| Combination data | EloraTZP Phase 2b (type 2 diabetes): 9 mg + tirzepatide 15 mg −23.3% at 48 weeks | Lilly press release, Sept 30, 2026 |
| Research format | Single 10 mg lyophilized vial; lot COA published on the product page | PSPeptides product page |
Sources: Lilly, “What to know about eloralintide” (updated September 2026); Briere et al., Molecular Metabolism 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026; Billings et al., The Lancet 2025; Lilly press releases of Nov 6, 2025 and Sept 30, 2026.

Eloralintide Peptide Structure and Receptor Pharmacology
Structurally, the eloralintide peptide is a 37-amino-acid synthetic analogue of human amylin. Three positions (11, 15 and 22) carry non-coded residues, the native disulfide bond is replaced by a methylene thioacetal bridge, and lysine 26 is acylated through two γ-glutamate linkers to a C20 fatty diacid that binds albumin, which is the structural reason for the two-week half-life (Briere et al., Molecular Metabolism 2025). No verified source reports a molecular weight, so none is stated here.
In cell-based cAMP assays on human receptors, eloralintide had an EC50 of 23.9 pM at AMY1R, 291.0 pM at the calcitonin receptor (about 12-fold weaker) and 253.8 pM at AMY3R (about 11-fold weaker). It is nevertheless a full agonist, with an Emax above 80%, at all three receptors, so “selective” describes a potency preference rather than an absence of calcitonin-receptor activity.
The discovery authors are careful on this point: they write that there is “no established minimum selectivity threshold” for biological relevance and that “further research is needed to characterize the in vivo selectivity profile.” Cagrilintide, characterised in the same paper, is a non-selective amylin receptor agonist with comparable potency at AMY1R, AMY3R and the calcitonin receptor. Whether the eloralintide peptide’s receptor preference translates into better tolerability is Lilly’s hypothesis, not an established fact.
Why Eloralintide Is Dosed Once Weekly
Across single doses of 0.4 to 12 mg, the eloralintide peptide showed a terminal geometric-mean half-life of 310 to 366 hours, or 12.9 to 15.3 days, with a median Tmax of 72 to 132 hours and dose-proportional exposure; the authors concluded that the profile “supports once-weekly dosing” (Briere et al. 2025). The 12-week multiple-dose study confirmed a half-life of about 14 days, “relatively flat” weekly concentrations and a steady-state peak-to-trough ratio of only 1.28 to 1.38 (Bhattachar et al., Diabetes, Obesity and Metabolism 2026).
Two practical consequences follow for anyone modelling the eloralintide peptide in a research protocol. Steady state takes roughly 2 to 2.5 months of weekly dosing, so a 12-week design spends most of its length still accumulating drug, and wash-out is slow: in the Phase 1b study, weight effects were still significant 9 to 10 weeks after the last dose at 6 and 12 mg. Our peptide half-life chart places that two-week figure next to other weekly peptides.
Phase 1 Single-Dose Study: The First Human Signal
Part A of NCT05295940 enrolled 48 healthy participants with a mean BMI of 27.5 in six cohorts of eight, six on eloralintide and two on placebo per cohort, and gave single subcutaneous doses of 0.04, 0.12, 0.4, 1.2, 4 or 12 mg (Briere et al. 2025). Weight was followed to day 29, which makes this the first human efficacy signal for the eloralintide peptide.
| Single subcutaneous dose | Participants | Day-29 mean weight change | Note |
|---|---|---|---|
| Placebo (two per cohort) | 12 | +0.6% | — |
| 0.04, 0.12, 0.4 and 1.2 mg | 6 per cohort | Not different from placebo | No efficacy signal below 4 mg |
| 4 mg | 6 | −2.5% | — |
| 12 mg | 6 | −4.4% | All GI events and the single injection-site reaction occurred in this cohort |
Source: Briere et al., Molecular Metabolism 2025 (Part A of NCT05295940; 48 healthy participants, mean BMI 27.5).
Tolerability at single doses was unremarkable: gastrointestinal events occurred in only 2 of 36 eloralintide recipients, and nausea, vomiting, dyspepsia, decreased appetite and the one injection-site reaction were all confined to the six people in the 12 mg cohort. There were no discontinuations and no serious adverse events.

Phase 1b: Twelve Weeks of Weekly Dosing Without Titration
Part B randomised 100 participants at three US centres to 12 weeks of the once-weekly subcutaneous eloralintide peptide or placebo with no dose titration at all: placebo 27, 1.2 mg 8, 3 mg 6, 6 mg 23 and 12 mg 36, followed by about 10 weeks off drug (Bhattachar et al. 2026). Starting straight at the full dose is the main design difference from the Phase 2 trial that followed.
| Weekly dose (no titration) | n | Week-12 LS-mean weight change | Nausea |
|---|---|---|---|
| Placebo | 27 | +0.2% | 0% |
| 1.2 mg | 8 | −2.6% | 0% |
| 3 mg | 6 | −8.9% | 0% |
| 6 mg | 23 | −8.5% | 13.0% |
| 12 mg | 36 | −11.3% | 8.3% |
Source: Bhattachar et al., Diabetes, Obesity and Metabolism 2026 (Part B of NCT05295940; 100 randomised; 12 weeks).
Weight change at week 12 was significant versus placebo for 3, 6 and 12 mg and remained so for 6 and 12 mg at week 21, the end of follow-up. The 3 mg arm appears to beat 6 mg (−8.9% versus −8.5%), but with six and 23 participants respectively that is noise, not a reversal of the dose response.
Even without titration, nausea was reported by 8% (6 of 73) of eloralintide recipients, diarrhoea by 10% and vomiting by 4%, against 0% for placebo, and nobody stopped for those reasons. Decreased appetite (19.2%), headache (12.3%) and fatigue (11.0%) were the most common events, and injection-site reactions ranged from 13.9% to 33.3% across active arms versus 3.7% on placebo.
Eleven eloralintide participants discontinued for adverse events, including three mood-related withdrawals, all in the 12 mg cohort, that resolved within 2 to 4 days; our eloralintide side-effects review examines that signal, which occurred above any Phase 2 dose.
Phase 2: 48 Weeks, Seven Arms, 263 Participants
The Phase 2 trial (NCT06230523) ran at 46 US sites from February 5, 2024 to August 14, 2025 and enrolled 263 adults aged 18 to 75 with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity, and no type 2 diabetes; baseline weight averaged 109.1 kg (Billings et al., The Lancet 2025). Participants were randomised 2:1:1:1:2:1:2 to placebo, 1, 3, 6 or 9 mg weekly, or one of two escalation arms.
The escalation schedules matter because they are often misquoted. The 6→9 mg arm took 6 mg for 20 weeks and then 9 mg for 28 weeks; the 3→6→9 mg arm took 3 mg for four weeks, 6 mg for four weeks and then 9 mg for the remaining 40 weeks. The eloralintide dosage guide lays both schedules out week by week with vial maths.
| Arm (once weekly) | n | Week-48 change, efficacy estimand | Treatment-regimen estimand | Nausea | Discontinued for AEs |
|---|---|---|---|---|---|
| Placebo | 53 | −0.4% (−0.2 kg) | −2.3% | 13.5% | 7.7% |
| 1 mg | 28 | −9.5% (−10.2 kg) | −7.3% | 11.1% | 11.1% |
| 3 mg | 24 | −12.4% (−13.3 kg) | −10.5% | 13.0% | 0% |
| 6 mg | 28 | −17.6% (−18.7 kg) | −13.8% | 64.3% | 21.4% |
| 9 mg | 54 | −20.1% (−21.3 kg) | −17.5% | 33.3% | 7.4% |
| 6→9 mg escalation | 24 | −19.9% (−21.0 kg) | −15.8% | 54.2% | 8.3% |
| 3→6→9 mg escalation | 52 | −16.4% (−17.8 kg) | −14.6% | 25.0% | 11.5% |
Source: Lilly press release, Nov 6, 2025 (efficacy estimand, all p<0.001 versus placebo); Billings et al., The Lancet 2025 (treatment-regimen estimand, nausea and discontinuation; safety population N=260).
Two estimands are reported. The efficacy estimand (on-treatment, the one used in the Lilly press release of November 6, 2025) gives −20.1% for fixed 9 mg; the treatment-regimen estimand, which keeps participants who stopped dosing, gives −17.5%, and the gap widens in arms with more drop-outs. Both are legitimate, but they are not interchangeable, and a table that mixes them will mislead.
Beyond the mean, Lilly’s ObesityWeek 2025 presentation of the trial reported that up to 57% of eloralintide participants lost at least 20% of body weight, that BMI fell by up to 7.9 kg/m² and waist circumference by up to 16.9 cm, and that in a DXA substudy 60 to 70% of the weight lost was fat (Hsia, Billings and Bays, ObesityWeek 2025); with no active comparator, none of that can be read as superiority over other agents. Arms held only 24 to 54 people, so every per-arm rate carries wide uncertainty; the eloralintide results review walks through each outcome measure in turn.
The tolerability pattern is the other half of the eloralintide peptide story. Nausea was similar to placebo at 1 and 3 mg (11.1% and 13.0% versus 13.5%), peaked at 64.3% in the fixed 6 mg arm and was 33.3% at fixed 9 mg; the slowest escalation, 3→6→9 mg, held nausea to 25.0% and vomiting to 1.9% but also delivered the least weight loss among the arms that reached 9 mg (−16.4%). Serious adverse events were 5.8% on placebo and 5.3% pooled across eloralintide arms, with no deaths.

EloraTZP: Eloralintide Plus Tirzepatide in Type 2 Diabetes
On September 30, 2026, at EASD in Milan, Lilly reported a 48-week, double-blind, placebo-controlled Phase 2b trial of the eloralintide peptide with tirzepatide in 367 adults with obesity or overweight and type 2 diabetes (T2D), run in the US and Argentina (Lilly press release, Sept 30, 2026). The two peptides were given as separate once-weekly injections; a co-formulation has not yet been tested in people.
| EloraTZP Phase 2b arm (48 weeks, T2D) | Week-48 weight change, efficacy estimand |
|---|---|
| Eloralintide 9 mg + tirzepatide 15 mg | −23.3% (−54.1 lb) |
| Eloralintide 6 mg + tirzepatide 10 mg | −19.9% |
| Eloralintide 6 mg + tirzepatide 5 mg | −19.4% |
| Eloralintide 3 mg + tirzepatide 5 mg | −13.2% |
| Tirzepatide 15 mg alone | −14.8% |
| Eloralintide 3 mg alone | −8.2% |
| Eloralintide 6 mg alone | −12.3% |
| Eloralintide 9 mg alone | −11.1% |
| Placebo | −3.0% |
Source: Lilly press release, Sept 30, 2026 (NCT06603571; 367 adults with obesity or overweight and type 2 diabetes).
Because every participant had T2D, the figures run lower than in non-diabetic trials, and the tirzepatide 15 mg arm (−14.8%) must not be set against SURMOUNT-1’s non-diabetic result; equally, the eloralintide-alone arms here (−8.2% to −12.3%) are not the Phase 2 numbers above. Discontinuation for adverse events was 10.8% to 27.0% in the combination arms, 0% to 10.8% on eloralintide alone, 2.9% on tirzepatide 15 mg and 16.7% on placebo.
Lilly plans to start Phase 3 studies of an EloraTZP co-formulation by the end of 2026. No human study has combined the eloralintide peptide with retatrutide, semaglutide or cagrilintide, so any such pairing in a research protocol has no clinical template; our EloraTZP article and tirzepatide research guide cover the one pairing that does.
How Eloralintide Differs From GLP-1 Agonists and From Cagrilintide
The eloralintide peptide is an amylin receptor agonist, whereas semaglutide, tirzepatide and retatrutide are incretin-receptor agonists working through GLP-1, GLP-1/GIP and GIP/GLP-1/glucagon receptors respectively. That separation is exactly why Lilly tested it on top of tirzepatide: in the same T2D trial, adding eloralintide 9 mg to tirzepatide 15 mg gave −23.3% where tirzepatide 15 mg alone gave −14.8%, a gain generated by a second pathway rather than a higher incretin dose.
The industry precedent for pairing an amylin analogue with an incretin is CagriSema, which combines cagrilintide with semaglutide; our CagriSema vs semaglutide comparison covers that programme. Against cagrilintide itself the distinction is receptor preference: cagrilintide is characterised as non-selective, with comparable potency at AMY1R, AMY3R and the calcitonin receptor, while the eloralintide peptide is AMY1R-preferential. No head-to-head trial exists, and the paper reporting the in vitro selectivity says its in vivo relevance still needs characterising.
Each pairing has its own page in this series, with durations, populations and placebo values side by side: eloralintide vs retatrutide, eloralintide vs tirzepatide and eloralintide vs semaglutide.
The ENLIGHTEN Phase 3 Program and What Lilly Has Not Disclosed
Lilly’s information page, last updated in September 2026, states that “Lilly is currently investigating eloralintide in Phase 3 trials” and that it “is now conducting Phase 3 trials of eloralintide as a monotherapy for the treatment of obesity.” Three registered trials make up the monotherapy program as of October 2026, each testing the eloralintide peptide in a different population.
| Trial | Population | Start | Estimated completion | Size and design notes |
|---|---|---|---|---|
| ENLIGHTEN-1 (NCT07321886) | Obesity or overweight without type 1 or type 2 diabetes; overweight participants need hypertension, dyslipidaemia, OSA or heart disease | Jan 1, 2026 | July 2030 | About 1,980 participants; placebo-controlled; doses not disclosed |
| ENLIGHTEN-2 (NCT07282600) | Obesity or overweight with type 2 diabetes | Dec 15, 2025 | Feb 2028 | About 1,035 participants; about 75 weeks and 20 visits; placebo-controlled; doses not disclosed |
| ENLIGHTEN-6 (NCT07392190) | Persistent obesity or overweight, with or without type 2 diabetes, in people already on a weekly incretin at screening | Feb 10, 2026 | July 2028 | About 900 participants; about 80 weeks and 22 visits |
Source: trial registry pages for ENLIGHTEN-1 and ENLIGHTEN-2 (linked above) and ENLIGHTEN-6 (clinicaltrials.gov/study/NCT07392190), accessed October 19, 2026.
What has not been disclosed is as important as what has: no Phase 3 doses, no readout dates and no filing or approval timeline have been published, and Lilly’s forward-looking statement gives “no assurance” that eloralintide will be approved. Estimated completion dates run from February 2028 to July 2030, so the first Phase 3 readouts are years away.

What the 10 mg Eloralintide Research Vial Is For
The eloralintide 10 mg vial at PSPeptides is a single lyophilized vial of the eloralintide peptide intended for laboratory work that models the protocols above: receptor studies, pharmacokinetic method development, or weekly-dosing designs built on the 1, 3, 6 and 9 mg Phase 2 arms. It is synthesized in a cGMP-compliant facility in Temecula, California, and every lot is tested by independent accredited laboratories for HPLC purity (99%+ minimum), mass-spectrometry identity, endotoxin, sterility, heavy metals and fentanyl, as set out on the certifications page; each lot’s batch-specific certificate of analysis is published on the product page.
Because 10 mg is a large quantity of a peptide studied at low-milligram weekly doses, concentration planning matters: 10 mg reconstituted in 1.0 mL of bacteriostatic water gives 10 mg/mL, so a 3 mg research dose is 0.30 mL, or 30 units on a U-100 insulin syringe. The free peptide calculator handles other volumes, and the eloralintide reconstitution guide covers technique for this vial, with the general peptide reconstitution guide for background. Orders placed before 2 PM EST ship the same day, US shipping is free, and cards, Afterpay and Klarna are accepted.
Buy eloralintide 10 mg — current pricing and the lot COA are on the product page.
Frequently Asked Questions About Eloralintide
What is eloralintide and who developed it?
The eloralintide peptide (LY3841136) is an investigational once-weekly amylin receptor agonist developed by Eli Lilly and designed to preferentially activate the amylin 1 receptor. It is a 37-amino-acid analogue of human amylin carrying a C20 fatty diacid that binds albumin and gives it a half-life of roughly two weeks.
Is eloralintide approved anywhere?
No. As of October 2026 eloralintide is not approved by the FDA or any other regulator, and Lilly describes it as investigational while three Phase 3 ENLIGHTEN trials are under way. Lilly has not disclosed Phase 3 doses, readout dates or a filing timeline.
How much weight loss did eloralintide produce in Phase 2?
In the 48-week Phase 2 trial of adults without type 2 diabetes, weekly doses of 1, 3, 6 and 9 mg produced body-weight changes of −9.5%, −12.4%, −17.6% and −20.1% on the efficacy estimand, against −0.4% for placebo. The treatment-regimen estimand, which keeps participants who stopped dosing, was lower at −17.5% for 9 mg.
How does eloralintide differ from cagrilintide?
Both are long-acting amylin analogues, but eloralintide was engineered as an AMY1R-preferential agonist with an EC50 of 23.9 pM at AMY1R against 291.0 pM at the calcitonin receptor, whereas cagrilintide is characterised as non-selective with comparable potency at all three receptors. No head-to-head trial has compared the two, so any tolerability advantage remains a hypothesis.
What doses of eloralintide were studied in humans?
Single doses of 0.04 to 12 mg of the eloralintide peptide were given in the Phase 1 study, weekly doses of 1.2 to 12 mg without titration in the 12-week Phase 1b study, and weekly doses of 1 to 9 mg, including two escalation schemes, in the 48-week Phase 2 trial. The EloraTZP Phase 2b trial paired 3, 6 or 9 mg of eloralintide with 5, 10 or 15 mg of tirzepatide.
References
- Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
- Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. https://doi.org/10.1016/j.molmet.2025.102271
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026;28(4):2651–2660. https://doi.org/10.1111/dom.70439
- Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
- Hsia S, Billings LK, Bays H. Eloralintide Phase 2 study in adult participants with obesity or overweight. Symposium presentation, ObesityWeek 2025 (Eli Lilly). https://assets.ctfassets.net/mpejy6umgthp/1SxVs7VHGLcnTF2V1Drf8w/936ff7e537ab94a8e92495efa09a0f23/VV-ELORAPT3_OW2025_HSIA_BILLINGS_BAYS_ELORALINTIDE_SYMPOSIUM_DV-033298_V3.2.pdf
- Eli Lilly press release, Sept 30, 2026 — “Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction…” https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
- ClinicalTrials.gov — ENLIGHTEN-1 (NCT07321886) https://clinicaltrials.gov/study/NCT07321886; ENLIGHTEN-2 (NCT07282600) https://clinicaltrials.gov/study/NCT07282600; ENLIGHTEN-6 (NCT07392190) https://clinicaltrials.gov/study/NCT07392190. Accessed October 12, 2026.
All PSPeptides products are sold exclusively for research and laboratory use.